Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

February 28, 2018

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Ezogabine

Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.

DRUG

Placebo

Matched placebo

Trial Locations (12)

10021

Hospital for Special Surgery, New York

17033

Penn State College of Medicine Milton S. Hershey Medical Center, Hershey

21287

Johns Hopkins Hospital, Baltimore

27705

Duke University Hospital, Durham

30901

Augusta University (Georgia Regents Medical Center), Augusta

32224

Mayo Clinic in Florida, Jacksonville

48109

University of Michigan, Ann Arbor

85013

Barrow Neuological Institute, Phoenix

90048

Cedars-Sinai, Los Angeles

92868

UC Irvine Medical Center, Orange

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ALS Association

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Harvard University

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Brian Wainger

OTHER

NCT02450552 - Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | Biotech Hunter | Biotech Hunter